Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced that the company plans to launch YUSIMRY™ (adalimumab-aqvh) in July 2023* with a list price of $995 per carton (2 x 40 mg/0.8 mL autoinjectors), the lowest price announced to date of any adalimumab offering in the United States. With Humira® currently priced at $6,922 per carton of two autoinjectors, the YUSIMRY price will represent about an 85% discount from the originator. YUSIMRY, a biosimilar of the reference product Humira® (adalimumab-injection) approved in 2021 by the United States Food and Drug Administration (“FDA”), is a
tumor necrosis factor (“TNF”) blocker indicated to reduce the signs and symptoms of
juvenile idiopathic arthritis,
psoriatic arthritis, and
ankylosing spondylitis, and to treat Crohn’s disease,
plaque psoriasis and
“Our YUSIMRY list price is a clear response to the challenges and needs of patients faced with high-cost adalimumab treatments today,” stated Denny Lanfear, Coherus CEO. “We believe there is a large, unmet need for improved access and affordability in the U.S. health care system that YUSIMRY can address with this pricing. Our excellence in manufacturing and supply chain management gives us the ability to deliver safe and effective biosimilar adalimumab at low cost with ensured, reliable supply.”
More than 300,000 patients in the U.S. take Humira each year, and Humira is among the top-selling drugs of all time, with 2022 net revenues in the United States of $18 billion.
The price of Humira has increased more than 500 percent since it was first launched in the U.S. in 2003 at $13,572 per year. The annual cost of Humira is now nearly $90,000, and the annual cost of YUSIMRY will be approximately $13,000, representing a discount of about 85%. In prior years, Coherus made significant investments in large-scale YUSIMRY manufacturing in order to be a high-volume, low-cost adalimumab producer. YUSIMRY has a state-of-the-art autoinjector presentation and includes Coherus’ proprietary non-stinging, citrate-free formulation and a 29-gauge needle.
"We believe that YUSIMRY can be an affordable solution for patients who are uninsured, underinsured, or recently separated from Medicaid coverage, who experience the most difficult financial health challenges. We also believe that employers and the employees on their health plans can experience significant savings by selecting YUSIMRY when it becomes available in July,” shared Chris Slavinsky, Coherus Chief Business Officer.
*No will occur, and no purchase orders will be accepted, until July 2023.
YUSIMRY™ (adalimumab-aqvh), a biosimilar of Humira® (adalimumab), is a tumor necrosis factor (“TNF”) blocker indicated to reduce the signs and symptoms of rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, and ankylosing spondylitis, and to treat
Crohn’s disease, ulcerative colitis, plaque psoriasis and hidradenitis suppurativa.
About Coherus BioSciences
Coherus is a commercial-stage biopharmaceutical company focused on the research, development and commercialization of innovative immunotherapies to treat cancer and the commercialization of our portfolio of FDA-approved therapeutics. Coherus’ strategy is to build a leading immuno-oncology franchise funded with cash generated through net sales of its diversified portfolio of FDA-approved therapeutics.
The content above comes from the network. if any infringement, please contact us to modify.